Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/24/2025

Management of Monoclonal Gammopathy

Diagnosis and Risk Stratification

  • The International Myeloma Society recommends diagnosing Monoclonal Gammopathy of Undetermined Significance (MGUS) in patients with a monoclonal protein level < 3 g/dL, fewer than 10% clonal plasma cells in the bone marrow, and no evidence of end-organ damage, with a risk of progression to multiple myeloma or other malignancies 1, 2
  • The Mayo Clinic stratification model identifies three prognostic factors for progression: monoclonal protein level ≥ 1.5 g/dL, non-IgG isotype (IgA or IgM), and abnormal free light chain (FLC) ratio (< 0.26 or > 1.65) 2, 3
  • Patients with a low-risk profile (0-1 risk factors) have a 2-10% risk of progression at 20 years, while those with a high-risk profile (3 risk factors) have a 27% risk of progression 2

Diagnostic Workup

  • The European Society for Medical Oncology recommends a diagnostic workup including serum protein electrophoresis, immunofixation, complete blood count, serum creatinine, calcium, and albumin, as well as FLC ratio and urine protein electrophoresis 1, 3
  • Bone marrow biopsy is not recommended for patients with IgG ≤ 1.5 g/dL without bone pain or other symptoms, but is recommended for all patients with IgA or IgM monoclonal proteins 3, 4
  • Imaging studies are not recommended for patients with IgG ≤ 1.5 g/dL or IgA ≤ 1.0 g/dL without bone pain, but may be considered for patients with higher levels of monoclonal protein or symptoms suggestive of end-organ damage 1, 4

Follow-up and Monitoring

  • The American Society of Hematology recommends follow-up every 2-3 years for patients with low-risk MGUS, with monitoring of monoclonal protein levels, complete blood count, serum creatinine, and calcium 2, 1
  • Patients with intermediate- or high-risk MGUS should be monitored more frequently (every 6-12 months) and may require bone marrow biopsy and imaging studies 1, 3
  • The International Myeloma Society recommends screening for osteoporosis and considering bisphosphonate therapy in patients with MGUS and osteoporosis or osteopenia 1, 4
  • Patients with MGUS should be monitored for signs of progression, including increasing monoclonal protein levels, anemia, hypercalcemia, renal insufficiency, bone pain, or recurrent infections 1, 2